Posted by Michael Wonder on 12 Jan 2017
European Commission grants marketing authorisation for Gilead’s Vemlidy (tenofovir alafenamide fumarate) for the treatment of chronic hepatitis B virus infection
11 January 2017 - Vemlidy is the first new treatment for chronic hepatitis B infection to be approved in the European Union in nearly a decade.
Gilead Sciences today announced that the European Commission has granted marketing authorisation for Vemlidy (tenofovir alafenamide fumarate) 25 mg, a once-daily tablet for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
The marketing authorisation allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland.
